Delgocitinib

Last updated

Delgocitinib
Delgocitinib.svg
Clinical data
Trade names Corectim, others
Other namesJTE-052; JTE-052A
AHFS/Drugs.com Monograph
MedlinePlus a625094
Routes of
administration 		Topical
ATC code
Legal status
Legal status
Identifiers
  • 3-[(3S,4R)-3-methyl-7-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1,7-diazaspiro[3.4]octan-1-yl]-3-oxopropanenitrile
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
CompTox Dashboard (EPA)
Chemical and physical data
Formula C16H18N6O
Molar mass 310.361 g·mol−1
3D model (JSmol)
  • C[C@H]1CN(C(=O)CC#N)[C@]12CCN(c1ncnc3[nH]ccc13)C2
  • InChI=1S/C16H18N6O/c1-11-8-22(13(23)2-5-17)16(11)4-7-21(9-16)15-12-3-6-18-14(12)19-10-20-15/h3,6,10-11H,2,4,7-9H2,1H3,(H,18,19,20)/t11-,16-/m0/s1
  • Key:LOWWYYZBZNSPDT-ZBEGNZNMSA-N

Delgocitinib, sold under the brand name Corectim among others, is a medication used for the treatment of autoimmune disorders and hypersensitivity, including inflammatory skin conditions. [5] Delgocitinib was developed by Japan Tobacco and approved in Japan for the treatment of atopic dermatitis. [5] Delgocitinib is a Janus kinase inhibitor that works by blocking activation of the JAK-STAT signaling pathway which contributes to the pathogenesis of chronic inflammatory skin diseases. [6]

Contents

Medical uses

In the EU and the US, delgocitinib is indicated for the topical treatment of moderate to severe chronic hand eczema in adults for whom topical corticosteroids are inadequate or inappropriate. [2] [3]

Society and culture

In July 2024, the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Anzupgo, intended for the treatment of chronic hand eczema. [3] [7] The applicant for this medicinal product is LEO Pharma A/S. [3] Anzupgo was authorized for medical use in the European Union in September 2024. [3] [4]

Delgocitinib was approved for medical use in the United States in July 2025. [8]

References

  1. ↑ "Product information". Health Canada . 28 August 2025. Retrieved 28 September 2025.
  2. 1 2 "HIGHLIGHTS OF PRESCRIBING INFORMATION" (PDF). accessdata.fda.gov. July 2025. Retrieved 20 October 2025.
  3. 1 2 3 4 5 "Anzupgo EPAR". European Medicines Agency. 25 July 2024. Retrieved 25 July 2024. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
  4. 1 2 "Anzupgo PI". Union Register of medicinal products. 23 September 2024. Retrieved 27 September 2024.
  5. 1 2 Dhillon S (April 2020). "Delgocitinib: First Approval". Drugs. 80 (6): 609–615. doi:10.1007/s40265-020-01291-2. PMID   32166597. S2CID   212681247.
  6. ↑ Szalus K, Trzeciak M, Nowicki RJ (November 2020). "JAK-STAT Inhibitors in Atopic Dermatitis from Pathogenesis to Clinical Trials Results". Microorganisms. 8 (11): 1743. doi: 10.3390/microorganisms8111743 . PMC   7694787 . PMID   33172122.
  7. ↑ "Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024". European Medicines Agency (Press release). 25 July 2024. Retrieved 29 July 2024.
  8. ↑ "LEO Pharma Announces FDA Approval of Anzupgo (delgocitinib) Cream in the U.S." (Press release). LEO Pharma. 23 July 2025. Retrieved 26 July 2025– via Business Wire.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.